CML Treatment in the Era of Operational Cure: Considerations for Therapy Selection Professor Giuseppe Saglio, University of Turin, Italy   Clinical case: Women, 39 years old including; Considerations for prognosis Considerations on the possibility of TFR ENESTnd study - 5 year update including cumulative incidence of MR4.5 Nilotinib is the only TKI registered for discontinuation Summary of Steering Group recommendations derived from patient-physician discussion Conclusion

This talk was first presented at EHA during the Satellite Symposium: 'Optimizing patient outcomes in CML and classical MPN's: New treatment paradigms and future developments' - supported by Incyte. You will find more education materials from EHA at the EHA Learning Centre.